BioInItaly Newsletter

La vetrina del biotech italiano all’estero
  • 29 lug, 2014
    CTI BioPharma expands access to PIXUVRI® with approval in Israel and add-on reimbursement status in the Netherlands
    The map of Tuscany life sciences companies makes easier investing and attracting resources
    Newron establishes US operations
    Newron shares to be included in the SXI Life Sciences® and the SXI Bio+Medtech® indices
    Nicox focuses US operations on national launches of Sjö(TM) and RetnaGene(TM) and restructures RPS® licensing agreement
    Lofarma is going to open to new markets
    Pancreatic Cancer meeting in Ravello sponsored by BIOUNIVERSA  (August 31st  - September 1st)
  • 08 lug, 2014
    Leading cancer institutes from Milan enter into major alliance with Biovitas Capital to generate new molecular diagnostics
    Nicox to acquire Aciex Therapeutics, Inc.
    Lofarma develops recombinant probiotics to treat allergies
    Purolite and c-LEcta collaborate to market CalB immo Plus™ immobilized enzyme
    Chicago and Tuscan bio-parks set collaboration agreement
    The intriguing dynasty of Citrus
    Explora Biotech’s Ulysses technology will design NEXT immune-shielding peptides
  • 06 mag, 2014
    Axxam launches the ion channelFLASH technology based on light mediated activation of voltage-gated ion channels
    MolMed reports top line results of NGR-hTNF in the phase III trial in malignant pleural mesothelioma
    PIXUVRI® launched in UK for adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
    Newron raises CHF18.6m in private placement to existing and new institutional shareholders in Europe and the USA
  • 07 apr, 2014
    STPS: New Italian bioplastics come from microbial fermentation
    MolMed: TK submission for Conditional Approval validated by EMA
    Nicox launches AdenoPlus® and Xailin(TM) dry eye product range in Europe
    Newron: New results with NW-3509 demonstrate potential of unique mechanism to benefit poor responders to antipsychotics in patients with schizophrenia
    Safinamide Application for Authorization submitted to Swissmedic
    Lofarma Biotechnology arrives at Russian Federation
  • 05 mar, 2014
    CTI: NICE Publishes Final Guidance on PIXUVRI® (pixantrone)
    AmerisourceBergen expands European presence with Herescon
    Nicox to re-focus naproxcinod on Duchenne muscular dystrophy
    Phase II results in Ataxia Telangiectasia published in Orphanet Journal of Rare Diseases
    Lofarma Biotechnology to fight Ragweed
    Takis – genetic cancer vaccine with proven efficacy for canine lymphoma being successfully evaluated in united states
  • 02 feb, 2014
    Intercept soars on liver disease data
    IpadLab has been identified as a top 10 cleantech SME in Italy
    The European Patent Office grants MolMed a new patent on its gene therapy platform
    Hit Discovery Constance GmbH: a new European hub for HTS and compound management
    Axxam and Cellectis bioresearch announce their collaboration to offer a new generation of cell based assays
    Newron Pharmaceuticals announced that J.P. Morgan Asset Management has taken a 1.8% stake in the Company
    Sequenom Laboratories grants Nicox exclusive promotion and marketing rights for its RetnaGene(TM) AMD test in North America
    MolMed provides an update on the registration strategy for its gene therapy TK in Europe and in the United States
    Cell Therapeutics Announces GOG Completes Patient Enrollment in GOG-0212 Phase 3 Clinical Trial of Paclitaxel Poliglumex (OpaxioTM) as Maintenance Therapy in Ovarian Cancer
    CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Phase 2 Trial Evaluating Pacritinib for Patients with Relapsed FLT3 Positive Acute Myeloid Leukemia
  • 08 gen, 2014
    EOS: an acquisition of $420 million by Clovis Oncology
    CTI: PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from NICE
    Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI® (pixantrone)
    Cell Therapeutics Receives $5 Million Milestone Payment for TRISENOX®
    Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
    Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement
    MolMed expands in Russia the Phase II trial of NGR-hTNF for the first line maintenance treatment of pleural mesothelioma
    MolMed: Long term assessment of immune reconstitution and related clinical benefit induced by TK treatment presented at the annual meeting of the American Society of Hematology
    Nicox - Major Progress in 2013 in Building an International Ophthalmic Company
    Nicox completes the acquisition of Eupharmed
    Sandoz receives first approval for AirFluSal® Forspiro®
    Gentium acquired by Jazz Pharmaceutical for $1bilion
    Newron Pharmaceuticals: Safinamide Marketing Authorization Application (MAA) submitted to EMA
    Novartis drug Jakavi® improved overall survival of patients with myelofibrosis in four separate analyses of long-term Phase III studies
    Lofarma establishes the Prize "Giuseppe Centanni"
    C.R.O. Aviano joins NETVAL technology transfer network
    Young innovators at C.R.O. Aviano
  • 03 dic, 2013
    Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI® (pixantrone)
    Cell Therapeutics Receives $5 Million Milestone Payment for TRISENOX®
    Nicox establishes commercial operations in Italy through acquisition of Eupharmed
    ARCHIMEDE R&D® launches the first catalytic water softening device
    Lofarma ploughs the profits back into allergy R&D
    MolMed & GSK: an agreement for the manufacture of the ADA-SCID gene therapy
    EryDel completes €15 million series B financing
    Gentium Receives a double Orphan Drug Designation for Defibrotide
    Baxter & Cell Therapeutics: a strategic collaboration to develop and commercialize Pacritinib
    Accelera enters an agreement with Karolinska Development as provider for pre-clinical research
    Italy became a founding member of BBMRI
  • 30 giu, 2013
    Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma
    Treatment, PIXUVRI® (pixantrone)
    EryDel SpA Completes €15 Million Series B financing
    Gentium Receives Positive Opinion from EMA’s CHMP for Defitelio
    Enzyme-loaded erythrocytes restore normal blood concentrations of Phenylalanine in a mouse model of Phenylketonuria (PKU)
    The European Patent Office grants MolMed a new patent on its anticancer drug NGR-hTNF
    Nicox Receives Positive Opinion for European Orphan Drug Designation for Naproxcinod for the Treatment of Duchenne Muscular Dystrophy
  • 03 mag, 2013
    EryDel SpA Announces EMA Orphan Drug Designation for EryDex for the treatment of Ataxia Telangiectasia                                                               
    MolMed: Long-term data presented at ASCO confirm prolonged survival times of patients with acute leukaemia treated with TK cell therapy
    Nicox Strengthens Ophthalmic Portfolio with Immco Diagnostics' Proprietary Test in the Dry Eye Market
  • 05 apr, 2013
    Presented the "Italian Biotechnology Report 2013" by Assobiotec and Ernst & Young
    EryDel announces US IND approval for EryDex
    Pre-clinical results on naproxcinod in models of muscular dystrophy presented at MDA Scientific Conference
  • 01 mar, 2013
    Turin will hosts Bio Europe Spring 2014
    Nicox strengthens its European and International Operations team and expands its product pipeline
    Tosedostat OPAL Study in Acute Myeloid Leukemia Published in Lancet Oncology Sardegna Ricerche will hold a workshop entitled "From Nanomedicine to Brain Imaging. New Frontiers in Nanobiotechnology"